A Study of HyQvia and Gammagard Liquid (Kiovig) in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

IDENTIFIERS
Trial Protocol: 161403
Clinicaltrials.gov: NCT02549170
EudraCT: 2014-005496-87
PURPOSE

This is a Phase III, prospective, multicenter study with two study parts (epochs) to evaluate the efficacy, safety, and tolerability of HYQVIA/HyQvia (IGI, 10% with recombinant human hyaluronidase (rHuPH20) administered subcutaneously) for maintenance therapy to prevent relapse (Epoch 1) and GAMMAGARD LIQUID/KIOVIG (immunoglobulin G intravenous (IGIV) 10% administered intravenously) for the treatment of CIDP (Epoch 2). This study will enroll adult subjects with a confirmed diagnosis of CIDP and who have remained on a stable dosing regimen (monthly equivalent dose of 0.4 to 2.4 g/kg body weight (BW) with a dosing interval of 2 to 6 weeks) of IGIV therapy for at least 3 months prior to screening. In this double-blind, placebo-controlled phase of the study (Epoch 1), eligible subjects will be randomized in a 1:1 ratio to receive either HYQVIA/HyQvia or 0.25% albumin placebo solution with rHuPH20 every two, three, or four weeks in a double-blind fashion for a period of 6 months or until relapse. Subjects who relapse during Epoch 1 will enter Epoch 2 to receive IGIV treatment for a period of 6 months.

Recruitment Complete
US
AR
BR
19+
CA
CO
HR
CZ
DK
FR
DE
GR
IL
IT
MX
NO
PL
RS
SK
ES
SE
TR
GB

Trial at a glance

What medical condition is being studied?   Chronic inflammatory demyelinating polyradiculoneuropathy
What is the trial testing?   HYQVIA; 0.25% albumin placebo solution with rHuPH20; IGIV
Are placebos part of the trial?   Yes
How many participants are being enrolled?   232
When is the trial being conducted?    - 
How long is participation in the trial?   Participants will take part in this study for about 8 months or 14 months, depending on which parts of the study they are in. Participants who are only in Part 1 will be in the study for about 8 months, and participants in both Parts 1 and 2 will be in the study for about 14 months.

Key requirements

Sex   
All
Age   
From 18 Years
Accepts Healthy Volunteers?   
No

Trial Details / Participation Requirements

CLICK TO EXPANDCLICK TO COLLAPSE
Trial Phase:   Phase 3
Trial Type:   Interventional
Trial Arms/Groups or Cohorts:   
Epoch 1: HYQVIA/HyQvia: Participants will receive HYQVIA/HyQvia at a dose of 80 Unit per gram (U/g) SC immunoglobulin (IgG) which will be same as the participants pre-randomization monthly equivalent IgG dose (or at matching infusion volume for participants in the placebo group) when administered at a dosing frequency of every 2, 3, or 4 weeks for 6 months or until relapse.
Epoch 1: Placebo with rHuPH20: Participants will receive sequential 0.25% albumin placebo with rHuPH20 at a dose of 80U/g IgG SC for 6 months or until relapse. Dosing regimen for placebo treatment will be the same as the participant's pre-randomization monthly equivalent IgG infusion volume when administered every 2, 3, or 4 weeks.
Epoch 2: IGIV: Participants will receive an induction dose of 2 gram per kilogram (g/kg) Intravenous immunoglobulin G (IGIV), followed by maintenance infusions at the same monthly dose as the participant's pre-randomization IgG dose, every 3 weeks for 6 months or until relapse.
Intervention:   HYQVIA; 0.25% albumin placebo solution with rHuPH20; IGIV
Primary Outcome Measure(s):   
Epoch 1: Relapse Rate on Every 2 Weeks Dosing Regimen (Q2W) at Pre-SC Baseline Week 1 [Time Frame: Pre-SC Baseline (Week 1)]
Epoch 1: Relapse Rate on Every 2 Weeks Dosing Regimen (Q2W) at Week 5 [Time Frame: Week 5]
Epoch 1: Relapse Rate on Every 2 Weeks Dosing Regimen (Q2W) at Week 9 [Time Frame: Week 9]
Epoch 1: Relapse Rate on Every 2 Weeks Dosing Regimen (Q2W) at Week 13 [Time Frame: Week 13]
Epoch 1: Relapse Rate on Every 2 Weeks Dosing Regimen (Q2W) at Week 15 [Time Frame: Week 15]
Epoch 1: Relapse Rate on Every 2 Weeks Dosing Regimen (Q2W) at Week 19 [Time Frame: Week 19]
Epoch 1: Relapse Rate on Every 2 Weeks Dosing Regimen (Q2W) at Week 23 [Time Frame: Week 23]
Epoch 1: Relapse Rate on Every 2 Weeks Dosing Regimen (Q2W) at Week 27 (End of Epoch 1 Treatment [EOE1T])/Unscheduled relapse visit assessment (UV)/Early Termination (ET) [Time Frame: Week 27 (EOET1)/UV/ET]
Epoch 1: Relapse Rate on Every 3 Weeks Dosing Regimen (Q3W) at Pre-SC Baseline [Time Frame: Pre-SC Baseline]
Epoch 1: Relapse Rate on Every 3 Weeks Dosing Regimen (Q3W) at Week 5 [Time Frame: Week 5]
Epoch 1: Relapse Rate on Every 3 Weeks Dosing Regimen (Q3W) at Week 8 [Time Frame: Week 8]
Epoch 1: Relapse Rate on Every 3 Weeks Dosing Regimen (Q3W) at Week 11 [Time Frame: Week 11]
Epoch 1: Relapse Rate on Every 3 Weeks Dosing Regimen (Q3W) at Week 14 [Time Frame: Week 14]
Epoch 1: Relapse Rate on Every 3 Weeks Dosing Regimen (Q3W) at Week 17 [Time Frame: Week 17]
Epoch 1: Relapse Rate on Every 3 Weeks Dosing Regimen (Q3W) at Week 20 [Time Frame: Week 20]
Epoch 1: Relapse Rate on Every 3 Weeks Dosing Regimen (Q3W) at Week 23 [Time Frame: Week 23]
Epoch 1: Relapse Rate on Every 3 Weeks Dosing Regimen (Q3W) at Week 26 (EOE1T)/Unscheduled relapse visit assessment (UV)/Early Termination (ET) [Time Frame: Week 26 (EOE1T)/UV/ET]
Epoch 1: Relapse Rate on Every 4 Weeks Dosing Regimen (Q4W) at Pre-SC Baseline [Time Frame: Pre-SC Baseline]
Epoch 1: Relapse Rate on Every 4 Weeks Dosing Regimen (Q4W) at Week 5 [Time Frame: Week 5]
Epoch 1: Relapse Rate on Every 4 Weeks Dosing Regimen (Q4W) at Week 8 [Time Frame: Week 8]
Epoch 1: Relapse Rate on Every 4 Weeks Dosing Regimen (Q4W) at Week 12 [Time Frame: Week 12]
Epoch 1: Relapse Rate on Every 4 Weeks Dosing Regimen (Q4W) at Week 16 [Time Frame: Week 16]
Epoch 1: Relapse Rate on Every 4 Weeks Dosing Regimen (Q4W) at Week 20 [Time Frame: Week 20]
Epoch 1: Relapse Rate on Every 4 Weeks Dosing Regimen (Q4W) at Week 24 [Time Frame: Week 24]
Epoch 1: Relapse Rate on Every 4 Weeks Dosing Regimen (Q4W) at Week 28 (EOET1)/Unscheduled relapse visit assessment (UV)/Early Termination (ET) [Time Frame: Week 28 (EOET1)/UV/ET]
Epoch 2: Responder Rate on Every 3 Weeks Dosing Regimen at Pre-Baseline (Week 1) [Time Frame: Pre-IV Baseline (Week 1)]
Epoch 2: Responder Rate on Every 3 Weeks Dosing Regimen up to 6 Months (End of Epoch 2 Treatment [EOE2T])/Unscheduled visit assessment (UV)/Early Termination [Time Frame: Up to 6 Months/UV/ET]
Secondary Outcome Measure(s):   
Epoch 1: Percentage of Participants Who Experience a Worsening of Functional Disability [Time Frame: Throughout Epoch 1, up to 6 months]
Epoch 1: Time to Relapse [Time Frame: Throughout Epoch 1, up to 6 months]
Epoch 1: Change From Pre-Subcutaneous (SC) Treatment Baseline in Rasch-built Overall Disability Scale (R-ODS) [Time Frame: Pre-subcutaneous (SC) treatment baseline, then weekly through Epoch 1 (up to 6 months); Unscheduled relapse visit assessment; & if early termination occurs.]
Epoch 1: Number of Participants Experiencing Any Treatment-Emergent Serious and/or Non-serious Adverse Events (SAEs and/or AEs), Regardless of Causality [Time Frame: Throughout Epoch 1, up to 6 months]
Epoch 1: Number of Participants Experiencing Causally Related Serious and/or Non-Serious Adverse Events (SAEs and/or AEs) [Time Frame: Throughout Epoch 1, up to 6 months]
Epoch 1: Number of Participants With Serious and/or Non-serious Adverse Reactions (ARs) Plus Suspected ARs [Time Frame: Throughout Epoch 1, up to 6 months]
Epoch 1: Number of Participants With Treatment-emergent Serious and/or Non-serious Adverse Events (SAEs and/or AEs) Associated With Infusions Regardless of Causality [Time Frame: Throughout Epoch 1, up to 6 months]
Epoch 1: Number of Participants With Causally Related Serious and/or Non-serious Adverse Events (SAEs and/or AEs) Associated With Infusions [Time Frame: Throughout Epoch 1, up to 6 months]
Epoch 1: Number of Participants With Adverse Events (AEs) Temporally Associated With Infusions [Time Frame: During an infusion or within 72 hours after completion of an infusion]
Epoch 1: Number of Participants With Serious and/or Non-serious Adverse Reactions (ARs) plus Suspected ARs Associated With Infusions [Time Frame: Throughout Epoch 1, up to 6 months]
Epoch 1: Number of Participants With Treatment-emergent Systemic Adverse Events (AEs) Associated With Infusions [Time Frame: Throughout Epoch 1, up to 6 months]
Epoch 1: Number of Participants With Treatment-emergent Local Infusion Site Reactions Associated With Infusions [Time Frame: Throughout Epoch 1, up to 6 months]
Epoch 1: Number of Infusions for Which the Infusion Rate Was Reduced And/Or the Infusion Was Interrupted or Stopped Due to Intolerability And/Or Adverse Events (AEs) [Time Frame: Throughout Epoch 1, up to 6 months]
Epoch 1: Rates of Systemic and Local Adverse Events (AEs), Regardless of Causality, Expressed as Number of Events Per Infusion [Time Frame: Throughout Epoch 1, up to 6 months]
Epoch 1: Rates of Systemic and Local Adverse Events (AEs), Regardless of Causality, Expressed as Number of Events per Participant [Time Frame: Throughout Epoch 1, up to 6 months]
Epoch 1: Rates of Systemic and Local Adverse Events (AEs), Regardless of Causality, Expressed as Number of Events per Participant-year [Time Frame: Throughout Epoch 1, up to 6 months]
Epoch 1: Rates of Causally Related Systemic and Local Adverse Events (AEs), Expressed As Number of Events Per Infusion [Time Frame: Throughout Epoch 1, up to 6 months]
Epoch 1: Rates of Causally Related Systemic and Local Adverse Events (AEs), Expressed As Number of Events Per Participant [Time Frame: Throughout Epoch 1, up to 6 months]
Epoch 1: Rates of Causally Related Systemic and Local Adverse Events (AEs), Expressed as Number of Events per Participant-year [Time Frame: Throughout Epoch 1, up to 6 months]
Epoch 1: Rates of Systemic and Local Adverse Reactions (ARs) plus Suspected ARs, Expressed as Number of Events per Infusion [Time Frame: Throughout Epoch 1, up to 6 months]
Epoch 1: Rates of Systemic and Local Adverse Reactions (ARs) plus Suspected ARs, Expressed as Number of Events per Participant [Time Frame: Throughout Epoch 1, up to 6 months]
Epoch 1: Rates of Systemic and Local Adverse Reactions (ARs) plus Suspected ARs, Expressed as Number of Events per Participant-Year [Time Frame: Throughout Epoch 1, up to 6 months]
Epoch 1: Number of Participants Who Develop Binding and/or Neutralizing Antibodies to Recombinant Human Hyaluronidase (rHuPH20) [Time Frame: Throughout Epoch 1, up to 6 months]
Epoch 2: Number of Participants Experiencing Any Treatment-emergent Serious and/or Non-serious Adverse Events (SAEs and/or AEs), Regardless of Causality [Time Frame: Throughout Epoch 2, up to 6 months]
Epoch 2: Number of Participants Experiencing Causally Related Serious and/or Non-serious Adverse Events (SAEs and/or AEs) [Time Frame: Throughout Epoch 2, up to 6 months]
Epoch 2: Number of Participants with Serious and/or Non-serious Adverse Reactions (ARs) plus Suspected ARs [Time Frame: Throughout Epoch 2, up to 6 months]
Epoch 2: Number of Participants With Treatment-emergent Serious and/or Non-serious Adverse Events (SAEs and/or AEs) Associated With Infusions Regardless of Causality [Time Frame: Throughout Epoch 2, up to 6 months]
Epoch 2: Number of Participants With Causally Related Serious and/or Non-serious Adverse Events (SAEs and/or AEs) Associated With Infusions [Time Frame: Throughout Epoch 2, up to 6 months]
Epoch 2: Number of Participants With Adverse Events (AEs) Temporally Associated With Infusions [Time Frame: During an infusion or within 72 hours after completion of an infusion]
Epoch 2: Number of Participants With Serious and/or Non-serious Adverse Reactions (ARs) plus Suspected ARs Associated With Infusions [Time Frame: Throughout Epoch 2, up to 6 months]
Epoch 2: Number of Participants With Treatment-emergent Systemic Adverse Events (AEs) Associated With Infusions [Time Frame: Throughout Epoch 2, up to 6 months]
Epoch 2: Number of Participants With Treatment-emergent Local Infusion Site Reactions Associated With Infusions [Time Frame: Throughout Epoch 2, up to 6 months]
Epoch 2: Number of Infusions for Which the Infusion Rate Was Reduced and/or the Infusion Was Interrupted or Stopped Due to Intolerability and/or Adverse Events (AEs) [Time Frame: Throughout Epoch 2, up to 6 months]
Epoch 2: Rates of Systemic and Local Adverse Events (AEs), Regardless of Causality, Expressed as Number of Events Per Infusion [Time Frame: Throughout Epoch 2, up to 6 months]
Epoch 2: Rates of Systemic and Local Adverse Events (AEs), Regardless of Causality, Expressed as Number of Events Per Participant [Time Frame: Throughout Epoch 2, up to 6 months]
Epoch 2: Rates of Systemic and Local Adverse Events (AEs), Regardless of Causality, Expressed as Number of Events Per Participant-year [Time Frame: Throughout Epoch 2, up to 6 months]
Epoch 2: Rates of Causally Related Systemic and Local Adverse Events (AEs), Expressed As Number of Events Per Infusion [Time Frame: Throughout Epoch 2, up to 6 months]
Epoch 2: Rates of Causally Related Systemic and Local Adverse Events (AEs), Expressed as Number of Events Per Participant [Time Frame: Throughout Epoch 2, up to 6 months]
Epoch 2: Rates of Causally Related Systemic and Local Adverse Events (AEs), Expressed as Number of Events Per Participant-Year [Time Frame: Throughout Epoch 2, up to 6 months]
Epoch 2: Rates of Systemic and Local Adverse Reactions (ARs) plus Suspected Ars, Expressed as Number of Events Per Infusion [Time Frame: Throughout Epoch 2, up to 6 months]
Epoch 2: Rates of Systemic and Local Adverse Reactions (ARs) plus Suspected ARs, Expressed as Number of Events Per Participant [Time Frame: Throughout Epoch 2, up to 6 months]
Epoch 2: Rates of Systemic and Local Adverse Reactions (ARs) plus Suspected ARs, Expressed as Number of Events Per Participant-Year [Time Frame: Throughout Epoch 2, up to 6 months]
Epoch 2: Percentage of Participants With Clinically Meaningful Improvement in Functional Ability [Time Frame: Throughout Epoch 2, up to 6 months]
Entry Criteria:
- Men and women 18 years or older can take part in this study. - Must have been diagnosed with definite or probable CIDP. - Must be on a stable dose of intravenous immunoglobulin G therapy for at least 12 weeks before starting the study. Additional entry criteria will be discussed with the study doctor.

Trial Locations

Any
Recruiting
Suspended
Terminated
Active, not recruiting
Any
RESULTS
Barrow Neurological Institute

350 W Thomas Rd, Phoenix, AZ 85013, USA

View on Map
HonorHealth Neurology

3501 N Scottsdale Rd Ste. 280A, Scottsdale, AZ 85251, USA

View on Map
Forbes Norris Mda/als Ctr

1100 Van Ness Ave 6th Floor, San Francisco, CA 94109, USA

View on Map
Regents of the University of colorado

13001 E 17th Pl ste f-428, Aurora, CO 80045, USA

View on Map
Immunoe Research Centers

6801 S Yosemite St, Centennial, CO 80112, USA

View on Map
University of Kansas Medical Center Research Institute, Inc.

3901 Rainbow Blvd, Kansas City, KS 66160, USA

View on Map
Rutgers New Jersey Medical School

185 S Orange Ave, Newark, NJ 07103, USA

View on Map
Wake Forest University

1834 Wake Forest Rd, Winston-Salem, NC 27109, USA

View on Map
University of Cincinnati

2600 Clifton Ave, Cincinnati, OH 45221, USA

View on Map
Cleveland Clinic

9500 Euclid Ave, Cleveland, OH 44195, USA

View on Map
Austin Neuromuscular Center

3901 Medical Pkwy #300, Austin, TX 78756, USA

View on Map
University Texas Physicians CAR

6410 Fannin St, Houston, TX 77030, USA

View on Map
Instituto de Neurologia de Curitiba - Hospital Ecoville

Rua Jeremias Maciel Perretto, 300 - Campo Comprido, Curitiba - PR, 81210-310, Brazil

View on Map
Hospital das Clínicas FMRP-USP

R. Ten. Catão Roxo, 3900 - Vila Monte Alegre, Ribeirão Preto - SP, 14015-010, Brazil

View on Map
LHSC - University Hospital

339 Windermere Rd, London, ON N6A 5A5, Canada

View on Map
Clinical Hospital Centre Rijeka

Krešimirova ul. 42, 51000, Rijeka, Croatia

View on Map
Clinical Hospital Centar Zagreb

Kišpatićeva ul. 12, 10000, Zagreb, Croatia

View on Map
CHU de Nice Hôpital Pasteur 2

30 Voie Romaine, 06000 Nice, France

View on Map
Hôpital de la Timone

278 Rue Saint-Pierre, 13005 Marseille, France

View on Map
Universitaetsmedizin Goettingen

Robert-Koch-Straße 40, 37075 Göttingen, Germany

View on Map
Universitaetsklinikum Leipzig AoeR

Liebigstraße 18, 04103 Leipzig, Germany

View on Map
University Hospital of Patra

Rio 265 04, Greece

View on Map
Azienda Ospedaliero Universitaria Pisana

Via Roma, 67, 56126 Pisa PI, Italy

View on Map
Instituto Nacional de Ciencias Médicas y Nutricion Dr. Salvador Zubiran

Vasco de Quiroga 15, Belisario Domínguez Secc 16, Tlalpan, 14080 Ciudad de México, CDMX, Mexico

View on Map
Samodzielny Publiczny Szpital Kliniczny Nr 4 w Lublinie

Jaczewskiego 8, 20-954 Lublin, Poland

View on Map
Uniwersytecki Szpital Kliniczny nr 1 im. Norberta Barlickiego

Dr. Stefana Kopcińskiego 22, 90-001 Łódź, Poland

View on Map
Clinical Center of Serbia

Pasterova 2, Beograd 11000, Serbia

View on Map
Military Medical Academy

Crnotravska 17, Beograd 11000, Serbia

View on Map
Clinical Center Nis

Bulevar Dr Zorana Đinđića 48, Niš 18000, Serbia

View on Map
Univerzitna nemocnica Bratislava Nemocnica ak. L. Derera, II. Neurologicka klinika

Ružinovská 4, 821 01 Ružinov, Slovakia

View on Map
Hospital Universitari Vall d'Hebron

Passeig de la Vall d'Hebron, 119, 08035 Barcelona, Spain

View on Map
Dokuz Eylul University Faculty of Medicine

İnciraltı, Otopark, 35330 Balçova/İzmir, Turkey

View on Map
Arizona Neuromuscular Research Center

4545 E Shea Blvd, Phoenix, AZ 85028, USA

View on Map
University of California-Irvine

Irvine, CA 92697, USA

View on Map
University of South Florida

4202 E Fowler Ave, Tampa, FL 33620, USA

View on Map
William Beaumont Hospital

3601 W 13 Mile Rd, Royal Oak, MI 48073, USA

View on Map
Hospital for Special Surgery

Hospital for Special Surgery, 535 E 70th St, New York, NY 10021, USA

View on Map
Hospital Italiano

Pres. Tte. Gral. Juan Domingo Perón 4190, C1199 ABH, Buenos Aires, Argentina

View on Map
Hospital Britanico de Buenos Aires

Perdriel 74, C1280 AEB, Buenos Aires, Argentina

View on Map
Complejo Medico de la Policia Federal Argentina Churruca Visca

Uspallata 3400, C1437 CABA, Argentina

View on Map
Instituto de Investigaciones Neurologicas Raul Carrea, FLENI

Montañeses 2325, C1428 AQK, Buenos Aires, Argentina

View on Map
HUAP - UFF - Hospital Universitario Antonio Pedro - Universidade Federal Fluminense

R. Marquês de Paraná, 303 - Centro, Niterói - RJ, 24033-900, Brazil

View on Map
Hospital das Clínicas da Faculdade de Medicina da UNICAMP

R. Vital Brasil, 251 - Cidade Universitária, Campinas - SP, 13083-888, Brazil

View on Map
Hospital Sao Paulo

Hospital São Paulo - Vila Clementino, São Paulo - SP, 04039-000, Brazil

View on Map
University of Alberta Hospital

8440 112 St NW, Edmonton, AB T6G 2B7, Canada

View on Map
Toronto General Hospital

200 Elizabeth St, Toronto, ON M5G 2C4, Canada

View on Map
Institucion Prestadora de Servicios de Salud de la Universidad de Antioquia "IPS UNIVERSITARIA"

Cl. 69 ##51c-24, Medellín, Antioquia, Colombia

View on Map
University Hospital Centre "Sestre Milosrdnice"

Vinogradska cesta 29, 10000, Zagreb, Croatia

View on Map
Fakultni nemocnice Brno

Jihlavská 340/20, 625 00 Brno-Bohunice-Brno-Starý Lískovec, Czechia

View on Map
Fakultni nemocnice Ostrava

17. listopadu 1790, 708 00 Ostrava-Poruba, Czechia

View on Map
Fakultni nemocnice v Motole

V Úvalu 84, 150 06 Praha 5, Czechia

View on Map
Groupe Hospitalier Pellegrin - Hôpital Pellegrin

Place Amélie Raba Léon, 33076 Bordeaux, France

View on Map
Hopital Neurologique Pierre Wertheimer

59 Boulevard Pinel, 69500 Bron, France

View on Map
Universitaetsklinikum Essen

Hufelandstraße 55, 45147 Essen, Germany

View on Map
Chaim Sheba Medical Center

Derech Sheba 2, Ramat Gan, Israel

View on Map
IRCCS Ospedale Casa Sollievo della Sofferenza

Viale Cappuccini, 1, 71013 San Giovanni Rotondo FG, Italy

View on Map
Istituto Clinico Humanitas

Via Alessandro Manzoni, 56, 20089 Rozzano MI, Italy

View on Map
Azienda Ospedaliera Universitaria Policlinico Tor Vergata

Viale Oxford, 81, 00133 Roma RM, Italy

View on Map
Azienda Ospedaliero Universitaria San Martino

Largo Rosanna Benzi, 10, 16132 Genova GE, Italy

View on Map
Azienda Ospedaliera Universitaria Policlinico G. Martino

Via Consolare Valeria, 1, 98124 Messina ME, Italy

View on Map
Casa di Cura del Policlinico

Via Giuseppe Dezza, 48, 20144 Milano MI, Italy

View on Map
Fondazione Istituto Neurologico Casimiro Mondino

Via Mondino, 2, 27100 Pavia PV, Italy

View on Map
Azienda Ospedaliera Universitaria Policlinico Umberto I - Università di Roma La Sapienza

Piazzale Aldo Moro, 3/5, 00185 Roma RM, Italy

View on Map
Azienda Ospedaliera Città della Salute e della Scienza di Torino

Corso Bramante, 88, 10126 Torino TO, Italy

View on Map
Azienda Ospedaliero-Universitaria Santa Maria della Misericordia

Piazzale Santa Maria della Misericordia, 15, 33100 Udine UD, Italy

View on Map
Oslo Universitetssykehus HF, Ullevål

Bygg 19, Gaustad Sykehus, Sognsvannsveien 21, 0188 Oslo, Norway

View on Map
COPERNICUS Podmiot Leczniczy Sp. z o. o.,

Nowe Ogrody 1-6, 80-803 Gdańsk, Poland

View on Map
Uniwersyteckie Centrum Kliniczne

Dębinki 7, 80-952 Gdańsk, Poland

View on Map
Fakultna nemocnica Nitra

Špitálska 6, 950 01 Nitra, Slovakia

View on Map
Hospital Universitari de Bellvitge

Carrer de la Feixa Llarga, s/n, 08907 L'Hospitalet de Llobregat, Barcelona, Spain

View on Map
Hospital de la Santa Creu i Sant Pau

Carrer de Sant Quintí, 89, 08041 Barcelona, Spain

View on Map
Hospital Universitario Virgen del Rocio

Av. Manuel Siurot, S/n, 41013 Sevilla, Spain

View on Map
Pamukkale Uni. Med. Fac.

Çamlaraltı, Pamukkale Ünv. Hastane Yolu, 20070 Kınıklı/Pamukkale/Denizli, Turkey

View on Map
Istanbul University Cerrahpasa - Cerrahpasa Medical Faculty

Cerrahpaşa, Koca Mustafapaşa Cd. No:53 D:No:53, 34096 Fatih/İstanbul, Turkey

View on Map
Selcuk Universitesi Selcuklu Tip Fakultesi Hastanesi

Ardıçlı, Akademi, Celal Bayar Cd. No:313, 42250 Selçuklu/Konya, Turkey

View on Map
Celal Bayar University Medical Faculty

Şehit Prof. Dr. İlhan Varank Kampüsü, Yağcılar, 45140 Yunusemre/Manisa, Turkey

View on Map
Southmead Hospital

Southmead Rd, Bristol BS10 5NB, UK

View on Map
King's College Hospital

Denmark Hill, Herne Hill, London SE5 9RS, UK

View on Map
The Walton Centre

Lower Ln, Liverpool L9 7LJ, UK

View on Map
Neurology Center of Las Vegas

2480 Professional Ct, Las Vegas, NV 89128, USA

View on Map
The Methodist Hospital Research Institute

6670 Bertner Ave, Houston, TX 77030, USA

View on Map
Århus Universitetshospital

P. P. Ørums Gade 11, 8000 Aarhus, Denmark

View on Map
Hallands sjukhus

Lasarettsvägen, 302 33 Halmstad, Sweden

View on Map
View all (83)
Trial Protocol ID: 161403
Back to Trial Summary